new zealand perspectives of hpv vaccination and genital tract neoplasia
Download
Skip this Video
Download Presentation
New Zealand Perspectives of HPV vaccination and Genital Tract Neoplasia

Loading in 2 Seconds...

play fullscreen
1 / 31

New Zealand Perspectives of HPV vaccination - PowerPoint PPT Presentation


  • 246 Views
  • Uploaded on

New Zealand Perspectives of HPV vaccination and Genital Tract Neoplasia. Sept 2006 Peter Sykes. Hpv 16/186/11. Age 9-26 3 vaccinations. MERCK. cervarix. Hpv 16/18. Cervical cancer is an important cause of mortality and morbidity particularly in developing countries. .

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'New Zealand Perspectives of HPV vaccination ' - Jimmy


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide2

Hpv 16/186/11

Age 9-26

3 vaccinations

MERCK

cervarix

Hpv 16/18

slide3
Cervical cancer is an important cause of mortality and morbidity particularly in developing countries.
  • Commonest in subsahara and central/south america
  • 1 in 10 cancers
  • 90% life lost in developing countries
hpv infection is an obligatory step in the development of cervical cancer
Sexual contact

Acute hpv infection

Persistent hpv infection

Integration of hpv DNA

Accumulation of mutation

Invasion

Normal

CIN 1/HPV

CIN2/3

Cancer

HPV infection is an obligatory step in the development of cervical cancer

10 to 30 yrs

barriers to hpv prevention
Barriers to HPV prevention
  • Prevalence of HPV infection
  • 30-40%14 and 15 yr old have had sex
  • Lack of culture medium
  • Numerous HPV types (96)
prevalence of hpv types in cervical cancer

14.6

16

18

69.7

45

25.7

17

52.5

67.6

12.6

31

33

57

52

58

Others

Prevalence of HPV Types in Cervical Cancer

HPV Type

North America/

Europe

South Asia

Northern Africa

Central/South America

*A pooled analysis and multicenter case control study (N = 3607)

1. Muñoz N, Bosch FX, Castellsagué X, et al. Int J Cancer. 2004;111:278–285.

hpv 16 and 18 vlp vaccines are a major medical advance
HPV 16 and 18 VLP vaccines are a major medical advance
  • Produces a stronger immune response than infection
  • No risk of infection
  • Prevents persistent infection
  • Has the potential to reduce the risk of cervical cancer by about 70%
  • Has the potential to reduce the risk of other hpv related cancers
vaccination hpv 16 18 almost eliminates 16 18 related disease at 24 months
Vaccination hpv 16, 18 almost eliminates 16/18 related disease at 24 months

Modified-intention-to-treat population

Subjects are counted once in each applicable endpoint category. A subject may appear in more than one category.

*Cases per 100 person years at risk.

n = received ≥ 1 vaccination; includes protocol violations; HPV 6, 11, 16 or 18 sero(-) and HPV 6, 11, 16 or 18 DNA(-) at Day 1; Cases counted starting one month post-dose 1

the impact of abnormal cervical cytology
The impact of abnormal cervical cytology
  • Psychological impact
  • Repeat cytology (cost)
  • Colposcopy
  • Treatment
  • Reproductive impact
  • Follow up colposcopy
  • Annual cytology
the burden of abnormal cytology in nz
The burden of abnormal cytology in NZ
  • 400,000 smears per annum
  • 30,000 abnormal
  • 4,000 have high grade smears
  • Approx 5,000 have high grade abnormalities that need treatment
  • Thousands more are treated for low grade abnormalities

CWH colposcopy Clinc

  • 1100 new patients
  • 3000 colposcopies
a large proportion of cervical abnormalities can be prevented by hpv vaccination
A large proportion of cervical abnormalities can be prevented by hpv vaccination
  • 63% CIN3 /AIS

hpv 6,11,18,16 pos

  • 40% CIN any grade hpv 6,11,18,16 pos
  • 10% reduction cin smear
  • 16% reduction in treatment cin
  • 25% reduction rx warts

Proportion of cin3 or worse assc with16,18,6,11.

genital warts are a common cause of unpleasant and troublesome morbidity
Genital warts are a common cause of unpleasant and troublesome morbidity
  • 1% sex active people
  • Require multiple RX
  • 30,000 sex heath clinic appts
  • 90% hpv 6 and 11
young new zealand women should be educated about hpv infection encouraged to undergo vaccination
Young New Zealand women should be educated about HPV infection encouraged to undergo vaccination
  • Vaccine well tested and no serious side effects
  • Demonstrated short term benefit reduction of CIN
  • Benefit likely regardless of sexual history
  • HPV testing not required
  • (prevention of warts gardasil)

BUT

  • Cervical screening recommendations are unchanged.
  • Long term benefits unproven (but likely)
  • Provided screening is adhered to the risk of cervical cancer is low.
cervical screening recommendations unchanged
Cervical screening recommendations unchanged
  • Current commercial tests do not allow investigation of HPV status pre vaccination.
  • Cervical screening below age 20 is not indicated.
  • Risk of CIN and cancer persists.
  • Interval of screening is dependent on natural history of disease and sensitivity of test.
slide16

A population based strategy of HPV vaccination has the potential to significantly reduce the future incidence of cervical cancer and other HPV related genital tract cancers.

slide18

In 2001 189 new registrations of cervical cancer

24 women anal, 42 vulval and 14 vaginal cancer.

slide19
Cervical cancer epidemiology is characterised by its falling incidence and mortality and inequalities of race and socioeconomic status
cervical cancer is most frequent in the poorly screened population
Cervical cancer is most frequent in the poorly screened population.
  • Older women
  • Maori
  • Immigrant population
  • Low Socioeconomic status
only a population based vaccination program will reduce cancer mortality
Only a population based vaccination program will reduce cancer mortality.
  • 100% effective given to 100% population may reduce incidence by 50-80%
  • Difficult to reach populations
  • Need to vaccinate prior to sexual activity
  • Lag time of 10-30 years
  • Immigrant populations may influence incidence
other considerations
Other Considerations
  • Long term data very limited
  • Unknown acceptance in NZ population
  • The epidemiology of HPV and cervical cancer could change
  • Vaccination could change screening behaviour
  • Other HPV related cancers may be increasing
slide24
The cost of a national vaccination program is likely to be difficult to justify on the basis of cancer prevention.
  • High cost of vaccine
  • Small number of lives saved
  • advanced age of women with advanced cancer
  • Current high expenditure on cervical cancer prevention
  • Competing vaccinations
  • Could the money be better spent
  • The vaccination of high incidence populations should be considered.
slide25
The cost benefit of prevention of screen detected abnormalities (and warts) by hpv vaccination must be carefully considered.
  • The cost of screen detected abnormalities need to be calculated.
  • The epidemiology of HPV serotypes and CIN in NZ needs further study
  • Long term vaccination data required
  • Modelling needs to account for future epidemiological and screening trends.
cervical cancer has a particular emotive impact
Cervical cancer has a particular emotive impact
  • Fear of cancer
  • Body image
  • Sexuality
  • Reproduction
  • Devastating symptoms
  • Stigma of STI
ethnic disparities of ca cervix
Ethnic disparities of Ca Cervix
  • Maori have greater incidence and mortality
  • Maori less uptake of screening
  • Greater delays in treatment
  • Poorer prognosis
  • Opportunistic vaccination could increase disparities
  • Population based vaccination could decrease them.
hpv vaccine in nz
HPV vaccine in NZ
  • Major Medical Breakthrough
  • HPV vaccination should be encouraged in young women

Cervical screening must continue

  • More information on the cost benefit of vaccination is required

The risk of cervical cancer in

screened women is very low

  • Funding is a Political issue
ad